In its own way, Shasqi Inc. will draw a crowd around next week's J.P. Morgan Healthcare Conference. Yes, José Mejîa Oneto's young San Francisco company has only eight employees and doesn't possess a deep portfolio of drugs. But Shasqi does offer a new way to boost the effectiveness and precision of drugs, launching its first cancer-fighting drug trial in humans in the second quarter.
